X

Trial Profile

A Phase 1b Trial of ARV-471 in Combination With Everolimus in Patients With ER+, HER2- Advanced or Metastatic Breast Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Aug 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary) ; Vepdegestrant (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer
Focus Adverse reactions
Acronyms TACTIVE-E
Sponsors Arvinas

Most Recent Events

19 Jan 2024 Status changed from recruiting to active, no longer recruiting.
11 Aug 2023 Planned End Date changed from 1 Feb 2024 to 30 Nov 2024.
11 Aug 2023 Planned primary completion date changed from 1 Aug 2023 to 30 May 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com